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Summary The structure/activity relationship of the protein kinase inhibitors, staurosporine and K 252a and
their analogues on motility of Walker carcinosarcoma cells has been studied in vitro. Staurosporine and
K 252a, similar to phorbol myristate acetate (PMA) and diacylglycerols, suppress cell polarity and locomotor
activity of Walker carcinosarcoma cells. Staurosporine inhibits spontaneous and colchicine-induced front-tail
polarity (IDm of about 6.0 x 10-8 M) as well as spontaneous and colchicine-stimulated locomotion at 10-7 M.
K 252a suppresses cell polarity (IDm of about 4.5 x 10-6M) and inhibits spontaneous and colchicine-
stimulated locomotion at I0-I M, but suppression of locomotor activity is not complete in the presence of
colchicine. CGP 41251, a staurosporine derivative with a much higher specificity for protein kinase C (PKC)
than staurosporine, induces a dose-dependent increase in the proportion of polarised cells, and stimulates cell
locomotion. Two K 252a analogues, KT 5720 and KT 5822, which act preferentially on cyclic nucleotide-
dependent protein kinases, and CGP 42700, an inactive staurosporine analogue, had no effect on cell polarity
and locomotion. The findings suggest that protein kinase inhibitors acting preferentially on PKC may be of
interest in pharmacological regulation of tumour cell locomotion.
Several mechanisms are instrumental in invasion and meta-
stasis. Among these, active tumour cell locomotion is thought
to play an important role, but relatively little is known on
the cellular mechanisms regulating the locomotor behaviour
of malignant neoplastic cells (Zimmermann & Keller, 1987).
In previous studies with Walker carcinosarcoma cells we
showed that the diacylglycerol (DAG)/protein kinase C
(PKC) pathway may be involved. Phorbol myristate acetate
(PMA; Keller et al., 1985) and diacylglycerols (diC8 and
OAG; Keller et al., 1989), which directly activate PKC,
suppressed both front-tail polarity and locomotion of Walker
carcinosarcoma cells in vitro. Activation of the PKC pathway
may generate a stop signal for the tumour cells (Keller et al.,
1989). Therefore, it was of interest to test whether agents
which inhibit PKC activity would exert an opposite effect.
Contrary to what we expected, PMA and DAGs vs the PKC
inhibitor H-7 did not produce opposing or antagonistic
effects on polarity and locomotion of Walker carcinosarcoma
cells (Keller et al., 1989). This observation indicated that the
postulated role of PKC needed to be analysed in more detail.
In the present work, a group of structurally closely related
kinase inhibitors was studied. This should allow for a more
detailed analysis of the putative roles of PKC vs other pro-
tein kinases, in particular the cyclic nucleotide-dependent
protein kinases (PKA and PKG) and to establish a structure/
activity relationship of inhibitory compounds. In the present
series of experiments we used staurosporine, K 252a, and
four of their chemical analogues, all of which are know to
interact with PKC, PKA and PKG with different specificity.
Materials and methods
Reagents andsuppliers
Human serum albumin (HSA; Behringwerke, Marburg, Ger-
many); colchicine and glutaraldehyde (Serva, Heidelberg,
Germany); phorbol 12-myristate 13-acetate (PMA; Sigma; St.
Louis, MO, USA); staurosporine and K 252a (Fluka, Buchs,
Switzerland); KT 5720 and KT 5822 were a kind gift from
Professor H. Kase, Tokyo Research Laboratories, Kyowa
Hakko Kogyo Co Ltd, Japan. CGP 41 251 and CGP 41700
were a kind gift from Ciba-Geigy Ltd., Switzerland.
The inhibition spectrum (data from the literature) of the
different protein kinase inhibitors used is summarised in
Table I. The chemical structure of the 6 agents used is shown
in Figure 1. Stock solutions were kept at - 80°C and thawed
immediately before use. DMSO which was used as solvent,
had no effect at the final concentration used. The basic
medium consisted of 2% HSA, 138 mM NaCl, 6mM KCI,
1 mM MgSO4, 1.1 mM CaC12, 100tLM EGTA, 1 mM Na2HPO4,
5 mM NaHCO3, 5.5 mM glucose, and 20 mM HEPES, pH 7.4.
Tumour cell culture, polarity and locomotor activity
Walker 256 carcinosarcoma cells, kindly provided by Dr B.
Sordat (ISREC, Lausanne), were kept in culture as
previously described (Keller et al., 1985). Viability was deter-
mined by means of the Trypan blue exclusion test. The
cultures were free of mycoplasma. For polarisation and
locomotion assays, cells were washed twice in Gey's solution
containing 2% HSA. Shape changes of suspended cells (final
cell density: 5 x IO' cellsml) were determined as previously
described (Keller, 1983; Keller & Zimmermann, 1986). At
least 100 cells per condition of each experiment were
analysed using Nomarski optics (DIC; Zeiss IM 35 micro-
scope, x 100 objective).
In the present series of experiments we tested the effects of
protein kinase inhibitors on the shape of unstimulated
tumour cells and of cells stimulated with colchicine (10-5 M).
In previous studies colchicine and other microtubule-
disassembling agents (nocodazole and vinblastine) have been
shown to increase the proportion of polarised and
Table I Inhibition spectrum ofdifferentproteinkinase inhibitorsused
(data taken from the literature)
In vitro enzyme inhibition (IC50, AiM) Compound PKC0 PKAb PKGc
Staurosporine 0.006"d 0.015d 0.0085e
CGP 41251 0.050d 2.4d ND
CGP 42700 > lood > lood ND
K252a 0.025f (0.22)' 0.018f (0.4)' 0.020f
KT 5720 >2.Of 0.06f >2.Of
KT 5822 0.079f 0.037f 0.002f
'Protein kinase C. bcAMP-dependent protein kinase. ccGMP-
dependent protein kinase. dMeyer et al., 1989. eProfessor N. Kase,
personal communication. fKase etal., 1987. gDrT. Meyer, unpublished
results. ND = Not determined.
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Figure 1 Chemical structures of the microbial alkaloids, K 252a and staurosporine, and of their respective derivatives. *Modified
from Kase et al. (1987). **Modified from Meyer et al. (1989).
locomoting Walker carcinosarcoma cells (Keller & Zimmer-
mann, 1986). Unstimulated cells exhibit a more or less
spherical shape with only small surface projections, whereas
polarised cells show a clearly visible front (with either ruffles
or bleb-like structures), an elongated cell body, and a con-
tracted tail. Cells with a non-spherical cell body, but with
projections all over the cell surface rather than at the front
were registered as nonpolar cells with surface projections, in
accordance with a terminology proposed and used with
leukocytes (Roos et al., 1987; Zimmermann et al., 1988).
Since Walker carcinosarcoma cells exhibited no or little
adhesiveness, the locomotor responses (Chemokinesis) of
cells (108ml-') had to be studied in narrow paraffin-sealed
slide-coverslip preparations (depth: 5-8 gm) in order to pre-
vent passive cell translocation. Observation of individual mi-
grating cells was performed on a heated (37°C) stage of an
inverted microscope (Keller et al., 1985; Keller & Zimmer-
mann, 1986). The path of individual cells was recorded on
videotape for 10min immediately after the preparation had
been set up. Longer incubation times had to be avoided
because the proportion of migrating cells was reduced to a
greater extent than the proportion of polarised cells in
suspension. This decrease in translocation appears to be due
to the very high cell densities which had to be used to record
sufficient numbers of cells in narrow chambers. The entire
path of cells was drawn on a transparency placed on the
screen of the TV monitor. Speed (i.e. distance travelled/min)
was determined by means of morphometry (IBAS; Zeiss;
Oberkochen, Germany). The proportion of migrating cells
represents the percentage of all cells which have locomoted
within the observation time of 10min. Since Walker car-
cinosarcoma cells may stop between periods ofmigration, the
proportion of cells migrating at a specific time point may be
lower. Only experiments with more than 20% migrating cells
in colchicine-treated controls were used to determine the
effects of staurosporine and related agents on locomotion.
Results
Staurosporine and CGP compounds
Effects on front-tail polarity Polarised tumour cells vs
spherical and nonpolar shapes were analysed because a close
correlation between the polarised phenotype ofcells and their
capability to locomote has been demonstrated (Keller &
Zimmermann, 1986). Fifty-six to 69% of the cells exposed to
10-5 M colchicine were polarised in the absence of stauro-
sporine as compared with about 43% in untreated controls.
Staurosporine produced a dose-dependent suppression of cell
polarity of both unstimulated tumour cells and of cells
exposed to 10-5 M colchicine (Figure 2). The IDs was about
6 x 10-8M for spontaneously polarised cells, and about
2 x 10-8 M for colchicine-treated cells. Maximum suppression
was obtained at 10-7 M to 3 x 10-7 M staurosporine. A reci-
procal increase in the proportion of nonpolar cells with
surface projections was observed (data not shown).
PMA, an activator of PKC, can suppress colchicine-
induced cell polarity (Keller et al., 1985). Staurosporine, an
inhibitor ofPKC, did not interfere with the suppressive effect
of PMA on colchicine-stimulated cell polarity (Figure 2,
bottom panel).
CGP 41251 is a staurosporine derivative (Meyer et al.,
1989; Figure 1) with a 9-fold lower affinity and a much
higher selectivity for PKC than staurosporine, H-7 and C-1.
CGP 42700 has no effect in vitro on any of the kinases up to
100gAM. The effects of CGP41251 and staurosporine have
been compared (Figure 2). CGP 4125,1 increased the propor-
tion of polarised cells, whereas staurosporine had an
inhibitory effect (upper panel). CGP 41251 had no inhibitory
effect on tumour cells polarised by colchicine (Figure 2,
middle panel).
In contrast to CGP 41251, the inactive staurosporine
analogue CGP 42700 (5 x 10-6 M and I0-5 M) had no effect
on cell polarity (data not shown).
In a further series of experiments the time course of the
effects of staurosporine, CGP 41251, and CGP 42700 was
tested. Staurosporine at 3 x 10-7 M inhibits front-tail polarity
of tumour cells at incubation times between about 5 min to
60 min (Figure 3). The inactive staurosporine analogue,
CGP42700, had no significant effect. CGP41251 led to a
rapid increase in the proportion of polarised cells, with a
half-maximum yield (i.e. about 30%) at 10 min, and maxi-
mum stimulation after 30 min.
Effects on locomotor activity Staurosporine alone at a con-
centration of 10-7 M did not significantly inhibit spontaneous
locomotion (Table II). The effect varied considerably fromEFFECTS OF PROTEIN KINASE INHIBITORS ON TUMOUR CELL LOCOMOTION 1079
one experiment to another (in three assays, staurosporine
alone led to a complete stop, a slight decrease, or even an
increase of locomotion). In contrast, staurosporine at 10-7 M
completely stopped locomotion in the presence of colchicine
(10-5 M).
CGP 41251 alone induced an increase in the percentage of
spontaneously migrating tumour cells, which agrees with its
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effect on cell polarity, as well as an increased speed of the
migrating subset (Table III). In the presence of colchicine
(10-' M), the locomotor activity was already fairly high and
could thus not be further stimulated.
K252a and its analogues
Effects on front-tail polarity Effects similar to those found
with staurosporine were observed with the related agent,
K 252a (see Table I). K 252a suppressed cell polarity in a
dose-dependent fashion (Figure 4), with an ID50 of about
4.5 x 10-6 M for spontaneously polarised cells and about
8.0 x 106 M for colchicine-treated cells. Thus, K 252a under
the assay conditions used appears to be about two orders of
magnitude less potent than staurosporine. These findings cor-
relate with data shown in Table I. The ID50 of K 252a for
unstimulated Walker carcinosarcoma cells is, however, very
close to that previously reported for the kinase inhibitor H-7
(4.5 x 10-6 M vs 6.5 x 10-6 M) using the same test conditions
(Keller et al., 1989). With K 252a an even higher increase in
the proportion of nonpolar cells with surface projections was
found than with staurosporine i.e. 70% (without colchicine),
at 10- M with an ED50 between 10-6 M and 3 x 10-6 M.
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Figure 2 Effects of Staurosporine and CGP 41251 on the
polarity of Walker carcinosarcoma cells. a, Spontaneously
polarised cells. b, Colchicine-stimulated cells. c, Cells treated with
colchicine and PMA. Cells were preincubated with or without the
respective stimulant at the concentrations indicated for 10 min at
37°C (0-*, staurosporine; *-*, CGP 41251). At the end of
this preincubation period either no stimulus, 10-5 M colchicine, or
I0-5M colchicine and 10-6 M PMA (staurosporine experiment
only) were added and incubation was continued for another
30 min. Cells were then fixed with 1% glutaraldehyde and the
morphology was analysed using Nomarski optics. Mean of 3
experiments ± s.d.m.
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Figure 3 Time course of the polarisation response to stauro-
sporine, CGP 41251 and CGP 42700. Walker carcinosarcoma
cells in 2% HSA-Gey solution (medium alone: *-@) were
stimulated with 3 x 10-7M staurosporine (A A), 10-5M
CGP41251 (E---E), or 10-5M CGP42700 (0 0). and the
time course of the morphologic response at 37°C was followed. a,
Polarised cells (front-tail polarity). b, Non-polar cells with surface
projections. Samples were removed and fixed with 1% glutaral-
dehyde at the time intervals indicated. Mean of 3 experi-
ments ± s.d.m.
Table II Inhibition of locomotion by staurosponne
Mean speed (ofall cells)
Additions to basic medium Percentage ofcells migrated Cum/min)
None 5.3 ±0.7 0.26 0.02
Staurosporine (10-' M) 3.6 + 2.7 0.26 ± 0.22
Colchicine (10-5 M) 26.6 ± 1.9 1.31 ± 0.09
Colchicine (10-5 M) 0 0
+ staurosporine (10-' M)
Meanof3experiments ± s.d.m. Cellswerefirstpreincubated inbasicmedium for 10 minat
37Candthenincubatedwithorwithouttheagentslistedinthetableforanother30 min.Then
slide-coverslip preparations were made to assess locomotion.
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Table III Effects of CGP 41 251 on locomotion
Percentage of Mean speed (ILm/min)
Additions to basic medium cells migrated All cells Migrating subset
None 2.3 4.0 0.10 0.17 1.42 2.46
CGP 41 251 (10-6 M) 13.3 3.9 0.57 0.15 4.33 ±0.20
Staurosporine (10-7 M) 2.9 ± 3.1 0.11 ± 0.12 2.78 ± 2.42
Colchicine (10-s M) 27.9 ± 4.3 1.91 ± 0.47 6.82 ± 0.59
CGP 41 251 (10-6M) 17.3 8.2 0.95 0.61 5.19 1.18
+ colchicine (10-5 M)
Staurosporine (10-7 M) 2.9 5.1 0.16 0.28 1.83 ± 3.17
+ colchicine (10-5 M)
Mean of3 experiments ± s.d.m. Cells were firstpreincubated in basicmedium for
10 min at 37°C and then incubated with or without the agents listed in the Table for
another 30 min. Then slide-coverslip preparations were made to assess locomotion.
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Figure 4 Effects of K 252a, KT 5822 and KT 5720 on the
polarity of Walker carcinosarcoma cells. a, Spontaneously
polarised cells. b, Colchicine-stimulated cells. c, Cells treated wtih
colchicine and PMA. Cells were preincubated with or without the
respective stimulant at the concentrations indicated for 30 min at
37-C (O 0, K252a; A---A, KT5822; 0-0, KT5720). At
the end of this preincubation period either no stimulus, l-5 M
colchicine, or 10-5 M colchicine and 10-6 M PMA were added
and incubation was continued for another 30 min. Cells were
then fixed with 1% glutaraldehyde and the morphology was
analysed using Nomarski optics. Mean of 3 experiments ± s.d.m.
KT 5720 is the 9-n-hexyl ester derivative of K 252a (Figure
1) and inhibits preferentially the cAMP-dependent protein
kinase (PKA). The 9-methoxy derivative, KT 5822 (Figure
1), was the most potent inhibitory compound for PKG
(Table I). KT 5720 and KT 5822 (10-12 M to 10- M) had no
effect on cell shape (Figure 3).
Effects on locomotor activity K 252a completely abolished
locomotion at IO-5 M (Table IV) in the absence of colchicine.
In the presence of colchicine, however, even 10-5 M K 252a
did not completely stop locomotion. The percentage of
locomoting cells decreased in parallel with the mean speed of
all cells. This indicates that the effects measured depend on a
reduction of the percentage of locomoting cells rather than
on a reduction of the speed of the locomoting subset.
KT 5720 and KT 5822 did not inhibit locomotion of
tumour cells in medium alone or in the presence of colchicine
(Table IV).
Discussion
Several mechanisms involved in growth, differentiation and
spread of tumour cells are modulated by a phosphoinositide-
protein kinase C (PKC) signal transducing pathway. Levels
of diacylglycerol (DAGs), which activate PKC, seem to be
increased in transformed cells (Preiss et al., 1986; Weyman et
al., 1988). An elevated DAG content of malignant cells may
derive from a constitutively enhanced DAG de novo
synthesis, and may cause long-lasting activation and down-
regulation of PKC (Chiarugi et al., 1989). Spread of malig-
nant tumour cells within the host organism can be modulated
by agents stimulating PKC. Depending on the cell line and
other variables phorbol myristate acetate (PMA) may inhibit
or stimulate the metastatic and/or invasive capacity of cells
(Takenaga & Takahashi, 1986; Gopalakrishna & Barsky,
1988; Fridman et al., 1990). Tumour cell polarity and
locomotion, which is thought to play a significant role in the
invasive process, is also modified by activators of PKC
(PMA, synthetic DAGs) in Walker carcinosarcoma cells in
vitro (Keller et al., 1985, 1989).
In order to further clarify the effects of protein kinase
modulation on the motile behaviour of Walker carcinosar-
coma cells we studied a group of structurally related
inhibitors of protein kinases, in particular of PKC (Kase et
al., 1987; Ruegg & Burgess, 1989; Meyer et al., 1989).It was
the aim of the present study to analyse whether staurosporine
and structurally related inhibitors of PKC have opposing
effects compared to activators of PKC such as PMA or
DAGs and whether inhibitors block the effects of PMA.
Furthermore, the study was designed to provide data on the
structure/activity relationship of these drugs. Walker car-
cinoma cells were chosen because this cell type has been shown
to exert both spontaneous and stimulated locomotion in vitro
(Keller et al., 1985), not withstanding the fact that this model
may not be representative for invasive human tumours.
Previous work using a less specific PKC inhibitor, H-7
(Hidaka et al., 1984), demonstrated that both activation and
inhibition of PKC may result in the same phenomenon, i.e.
suppression of locomotion of Walker carcinosarcoma cells
(Keller et al., 1989). The present work shows that stauro-
sporine and K252a, two alkaloid-type PKC inhibitors act
similar to H-7. They suppress polarity and locomotion of
Walker carcinosarcoma cells. Interestingly, however, CGP
41251, which has a higher selectivity for PKC than all other
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Table IV Effects of K 252a, KT 5720 and KT 5822 on locomotion
Additions to basic medium Percentage cells migrated Mean speed (ofall cells)
K252a
None 5.5 1.7 0.3±0.1
K 252a (10-7M) 4.2 2.1 0.2 0.1
K252a(10-5M) 0 0
Colchicine (10-5 M) 29.6 ± 1.0 1.6 + 0.05
Colchicine (10-I M) 16.3 ± 3.0 0.9 + 0.3
+ K 252a (10-7 M)
Colchicine (10-5M) 10.6 + 1.7 0.5 ± 0.1
+ K 252a (10-5 M)
K5720
None 27.4 8.7 1.15 0.45
KT5720(10-7M) 29.9±6.1 1.57±0.28
Colchicine (10-5 M) 54.6 ± 7.5 3.67 ± 0.35
Colchicine (10-5 M) 49.0 ± 7.1 3.07 ± 0.27
+ KT 5720 (10-7 M)
KT5822
None 33.1 6.3 1.83 0.43
KT5822 (10-7M) 35.8±2.0 1.40±0.29
Colchicine (10-5 M) 53.0 ± 6.3 3.07 ± 0.43
Colchicine (10-5 M) 54.1 ± 9.6 2.83 ± 0.87
+ KT 5822 (10-7 M)
Mean of 3 experiments ± s.d.m. Cells were first preincubated in basic medium for
10 min at 37'C and then incubated with or without the agents listed in the Table for
another 30 min. Then slide-coverslip preparations were made to assess locomotion.
inhibitors including staurosporine (see Table I; Meyer et al.,
1989), induced a dose-dependent increase in the proportion
of polarised and of migrating cells.
Our findings suggest that PKC itself plays a more
significant role in regulating locomotion than cyclic
nucleotide-dependent protein kinases. Inhibitors (KT 5720,
KT 5822) preferentially acting on this class of kinases were
inactive. Modifications at the 9-hydroxy or 9-methoxy-
carbonyl moieties of the K 252 molecular core (see Table I;
Kase et al., 1987) thus appear to drastically change the
inhibitory profiles for protein kinases, and the biological
effects. Protein kinase inhibitors with a relatively high selec-
tivity for PKC, i.e. staurosporine, K 252a and CGP 41251
produced diverse effects on cell polarity and locomotion. We
initially speculated that the PKC inhibitors staurosporine,
K 252a or CGP 41251 vs activators of PKC might have
opposing effects. PMA suppresses polarity and locomotion
but only CGP 41251, i.e. the compound with the highest
selectivity for PKC stimulated polarity and locomotion. In
contrast, staurosporine and K 252a suppressed polarity and
locomotion similar to PMA. Thus, only the inhibitor with
the highest selectivity for PKC (i.e. CGP 41251) has effects
opposite to active phorbol esters. Inhibitors with a lower
selectivity (staurosporine, K 252a) have more complex inhibi-
tion profiles and their effect may not be sufficiently represen-
tative for mere PKC inhibition. They may therefore affect
biological responses through several different mechanisms
(including PKC) which are not yet sufficiently clear. It has
been suggested, that the rapid increase in cytoskeleton-
associated actin of neutrophils exposed to staurosporine is
due to inhibition of an unknown staurosporine-sensitive
enzyme, not identical with PKC or one of the cyclic-nucleo-
tide-dependent kinases (Niggli & Keller, 1991). Furthermore,
inhibitors of the staurosporine type seem to possess phorbol
ester agonistic as well as antagonistic effects (Dlugosz &
Yuspa, 1991). Interestingly, both staurosporine and PMA
induce association of PKC with the neutrophil membrane
(Wolf & Baggiolini, 1988) and a dendritic shape in
keratinocytes (Sako et al., 1988).
It is at present also rather difficult to properly understand
the mechanisms involved in the action of K 252a. Several
studies on K 252a also show that a biological response with a
PKC inhibitor may not only depend on PKC inhibition, but
may also be related to other mechanisms. K 252a seems to
act on PKC as well as on PKC-like, but calcium-unres-
ponsive protein kinases (p82 kinase and p76 kinases; the IC50
of K 252a with regard to PKC and the p76-kinase differing
by two orders of magnitude; Gschwendt et al., 1989). In
contrast to PKC, K 252a at concentrations of up to
5 x 1O- M fails to suppress p76 kinase activity, but it
inhibits PKC-catalysed phosphorylation up to 50%. Further-
more, inhibition ofprotein phosphorylation by K 252a is still
effective when the process of PMA-mediated down-regulation
is completed, but K252a does not influence PMA-induced
down-regulation of PKC at all (Lindner et al., 1991). Loss of
K 252a-induced kinase inhibition through enzyme decay and
eventual consecutive formation of catalytically active frag-
ments (e.g., 50 kDa kinase M, which can phosphorylate
phosphatidylinositol-4-phosphate; (Tusupov et al., 1991) does
not appear to represent a probable mechanism. Differential
effects on cell motility may theoretically also depend on
varying drug interactions with PKC isoforms. At least eight
subspecies of PKC have been identified with differences in
structure, substrate, and calcium dependence (Nishizuka,
1988; Bacher et al., 1991). Interestingly, PMA treatment of
intact epithelial cells increased the level ofphosphorylation of
major cytoskeletal compounds, i.e. cytokeratins 8/18 (Chou
& Omary, 1991). An isoform (PKC epsilon)-related kinase
associates with and phosphorylates cytokeratins 8 and 18
(Omary et al., 1992). As the cytoskeleton controls cell shape
and locomotion it will be of interest to test PKC inhibitors
with regard to PKC subspecies.
Further insight into possible mechanisms may be gained by
looking at the molecular structure. CGP41 251 (Figure 1)
has an aromatic ring (a benzoyl group) bound to nitrogen in
close vicinity to a methyl group and a methoxy group, which
after binding to PKC may alter the enzyme's interactions
with a lipid environment (for review, see Bell & Bums, 1991).
One may theorise that binding of an agent with a hydro-
phobic cluster, such as CGP41 251, may modify the interac-
tion with phosphatidyl-serine molecules located in cellular
membranes, or modify the binding to other cell components.
One mechanism may be of particular interest for understan-
ding the effects of PKC-inhibitors on cell shape and motility.
PKC does not only bind to membrane lipids, but may
interact with cytoskeletal proteins in the particulate fraction
and in the nuclei. Binding of PKC to two of these proteins
(receptors for activated C kinase, 'RACKS') was con-
centration-dependent, saturable, and specific (Mochly-Rosen
et al., 1991). PKC binds to RACKS via a site on PKC
distinct from the substrate binding site. It has been suggested
that binding to RACKS may play a role in activation1082 A. ZIMMERMANN & H. KELLER
(DAG)-induced translocation of PKC (Mochly-Rosen et al.,
1991), but RACK binding may theoretically also be altered
by PKC-bound agents such as CGP 41 251.
Further studies with an extended set of alkaloid analogues
with high specificity for PKC are required. Staurosporine and
K 252a may not be sufficiently representative tools to study
effects specifically related to PKC-inhibition.
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